Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Fifty-nine percent of consumers who use digital health apps and tools suffer from a chronic condition, but only 7 percent are using a disease management tool, according to a March HealthMine survey of 500 insured consumers.
The U.S. market for active aging technology now encompasses 85 million Americans or more than one quarter of the national population, according to a new report from the Consumer Technology Association and the CTA Foundation.
As many other industries have successfully shifted to business models centered on customer interaction, healthcare companies, and in particular health insurance companies, seem to have fallen behind the pack.
The healthcare industry is well aware that physician rating websites are bigger now than ever before. But do parents use these sites? Do they trust them?
About two-thirds of providers report that telemedicine is a one of their organization’s highest priorities, according to the results from the REACH Health 2016 U.S. Telemedicine Industry Benchmark Survey. That represents a 10 percent increase from the 2015 survey results.
The Innovation & Digital Health Accelerator (IDHA) and Autoinflammatory Diseases Clinic at Boston Children's Hospital have released Feverprints, a ResearchKit app for iPhone that will enlist the public's help to determine what exactly is a fever.
At least for a little while, “our kid got to be normal.” Those were the tearfully happy words of a dad whose hospitalized child had just eagerly received relief in the form of a fun, mood-boosting virtual reality experience.
The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.
